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Poster Session II S331initaiated on day 5. Various surveillance investigations for viral and
fungal infections are utilized at the centers. The majority of centers
utilized hyperalimentation (96%) in their patients with 57% of the
centers using enteral feeds in conjunction with hyperalimentation.
Conclusion: Based on the responses submitted by the PBMTC
membership, the programs employ various supportive care practices.
These findings suggest a need to develop evidence based clinical
practice guidelines in the care of the pediatric BMT patient.478
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The overall colonization rates of Vancomycin-resistant entero-
coccus (VRE) in patients with cancer and other chronic diseases
are high. On an inpatient unit combining Hematopoietic Stem
Cell Transplant (HSCT) patients with general hematology, oncol-
ogy, nephrology and orthopedic patients the high colonization
rates of VRE in these populations may be another risk factor for
transmission to HSCT patients in addition to their prolonged neu-
tropenia and multiple antimicrobial medications. VRE bacteremiasduring HSCT have been associated with high morbidity and mor-
tality. During the first quarter of 2009, 4 of our transplant patients
had symptomatically positive VRE stool cultures and 1 also had
VRE bacteremia. One of theses patients had sickle cell disease
and had no history of prolonged use of antibiotics prior to his pos-
itive VRE stool culture. All patients tested positive for the same
VRE strain, which was also identified in a non-transplant patient
hospitalized on the same inpatient unit. Therefore, a multidisciplin-
ary (Microsystems) team was established within our department to
implement and monitor the recommended infection prevention
measures put forth by the Center for Disease Control (CDC)
and Joint Commission. The multidisciplinary team was comprised
of staff from the inpatient and outpatient units, infection control,
environmental services and administration. The areas of focus in-
cluded judicious use of antibiotics, education of staff, patients
and families regarding hand hygiene compliance, standard and con-
tact precautions recommendations and adherence, and surveillance
for VRE. Patient and family surveys were conducted to identify the
possible causes of VRE transmission and educational needs of staff,
patients and families. A ‘‘VRE+’’ sticker was placed on the cover of
the patient’s medical chart and VRE positive status was communi-
cated to all ancillary care services. Our team met bi-weekly to up-
date the process. Through these interventions and the
reinforcement of the VRE policy, we are pleased to report there
have been no new patients with VRE infection in the second and
third quarter of the year for our inpatient and outpatient Hematol-
ogy and Oncology Units.
